Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07. Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting of Stockholders (the Annual
Meeting) on April17, 2017. As of February17, 2017, the record
date for the Annual Meeting, there were 22,556,038 outstanding
shares of the Companys common stock. The Companys stockholders
voted on the following matters, which are described in detail in
the Companys Definitive Proxy Statement filed with the U.S.
Securities and Exchange Commission (SEC) on March6, 2017: (i)to
elect Daniel Janney, Tim M. Mayleben and Mark E. McGovern, M.D.,
as ClassI directors of the Company to each serve for a three-year
term expiring at the Companys annual meeting of stockholders in
2020 and until their successors have been elected and qualified
(Proposal 1), (ii)to approve the advisory resolution on the
compensation of the Companys named executive officers (Proposal
2), and (iii)to ratify the appointment of Ernst Young LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017 (Proposal 3).

The Companys stockholders approved the ClassI director nominees
recommended for election in Proposal 1 at the Annual Meeting. The
Companys stockholders voted for ClassI directors as follows:

The Companys stockholders approved Proposal 2. The votes cast at
the Annual Meeting were as follows:

The Companys stockholders approved Proposal 3. The votes cast at
the Annual Meeting were as follows:

No other matters were submitted to or voted on by the Companys
stockholders at the Annual Meeting.

* * *

About Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Recent Trading Information

Esperion Therapeutics, Inc. (NASDAQ:ESPR) closed its last trading session up +0.40 at 37.38 with 580,646 shares trading hands.